Global Rheumatoid Arthritis Drugs Market

Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By Molecule(Pharmaceuticals, Biopharmaceuticals), By Sales Channel(Prescription, Over-the-counter (OTC)), By Region - Industry Forecast 2024-2031


Report ID: SQSG35I2003 | Region: Global | Published Date: October, 2024
Pages: 242 | Tables: 115 | Figures: 69

Rheumatoid Arthritis Drugs Market News

  • In January 2024, AbbVie disclosed its recent expansion of indications for Rinvoq (upadacitinib), a new biological drug for the treatment of moderate to severe rheumatoid arthritis that received an approval by the FDA. The approval was obtained through the regulatory authorities for a new set of indications thus offering a better oral treatment alternative for patients who fail to respond to conventional treatment. 
  • In March 2024, Pfizer announced the positive results of a Phase 3 trial for its JAK (Janus kinase) inhibitor under development PF-06651600 for rheumatoid arthritis treatment. Improved patient outcomes with respect to inflammation and joint destruction were noted after treatment, indicating that the drug has the potential to be one of the rheumatoid arthritis therapeutic agents. 
  • In February 2024, Roche has successfully obtained regulatory authorization for its latest biologic product – Evrysdi (risdiplam) – which is indicated for the treatment of rheumatoid arthritis. This approval followed the outcome of clinical trials that showed considerable symptomatic and functional improvements in patients suffering from rheumatoid arthritis, thus reinforcing the company’s line of treatments for autoimmune disorders and its leadership in the market. 
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Rheumatoid Arthritis Drugs Market size was valued at USD 23.61 billion in 2022 and is poised to grow from USD 25.01 billion in 2023 to USD 39.65 billion by 2031, growing at a CAGR of 5.93% in the forecast period (2024-2031).

Competitive Landscape  'AbbVie, Inc. (US) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Novartis AG (Switzerland) ', 'Regeneron Pharmaceuticals Inc. (US) ', 'Pfizer Inc. (US) ', 'Bristol Myers Squibb Company (US) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'UCB S.A. (Belgium) ', 'Johnson & Johnson Services, Inc. (US) ', 'Amgen, Inc. (US) ', 'Lilly (Eli Lilly and Company) (US) ', 'CELGENE CORPORATION (US) ', 'Gilead Sciences, Inc. (US) ', 'Bausch Health (Canada) ', 'Merck & Co., Inc. (US) ', 'Viatris Inc. (US) ', 'LEO Pharma (Denmark) ', 'Celltrion Inc. (South Korea) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Teva Pharmaceuticals Industries Ltd. (Israel)'

The increasing impact of rheumatoid arthritis around the globe is one of the most important propellers for the expansion of the global rheumatoid arthritis drugs market. As the case of elder population, that it is on the rise, and the eating habits of people are responsible for the incidence of this disease rheumatoid arthritis in addition there is a rising need for effective measures that will help treat this condition which enhances market development. 

Growing Adoption of Biologic Therapies: In the global rheumatoid arthritis drugs industry, medicaments for treatment are developing towards biologics applications which include monoclonal antibodies and JAK inhibitors. Such modern drugs provide targeted action and hence, more desirable results with fewer side effects. The increasing uptake is due to their efficacy in dealing with moderate to severe cases of rheumatoid arthritis. 

North America is dominating the global rheumatoid arthritis drugs market due to a combination of factors, including high healthcare spending, advanced healthcare infrastructure, and robust research and development activities. The region has a vast clientele base, due to the changing age demographics, increasing rheumatoid arthritis awareness resulting in a greater need for new therapies. Besides, the region is also advanced in therapeutics with access to state-of-the-art biologics, DMARDs, JAK inhibitors alongside an improving drug regulatory regime which fast-tracks drug registration processes. Furthermore, the existence of large pharmaceutical corporations and the rise of individualized medicine are other reasons as to why North America has the highest market share for rheumatoid arthritis therapeutics. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Rheumatoid Arthritis Drugs Market

Report ID: SQSG35I2003

$5,300
BUY NOW GET FREE SAMPLE